Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.

AB, Cavalcanti; FG, Zampieri; RG, Rosa; LCP, Azevedo; VC, Veiga; A, Avezum; LP, Damiani; A, Marcadenti; L, Kawano-Dourado; T, Lisboa; DLM, Junqueira; Barros E Silva PGM, de; L, Tramujas; EO, Abreu-Silva; LN, Laranjeira; AT, Soares; LS, Echenique; AJ, Pereira; FGR, Freitas; OCE, Gebara; VCS, Dantas; RHM, Furtado; EP, Milan; NA, Golin; FF, Cardoso; IS, Maia; Filho CR, Hoffmann; APM, Kormann; RB, Amazonas; de Oliveira MF, Bocchi; A, Serpa-Neto; M, Falavigna; RD, Lopes; FR, Machado; O, Berwanger

doi:10.1056/nejmoa2019014

Public

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.

Shared by NobleBlocks on Jul 23, 2020 • 12:00 AM UTC

Authors:

Cavalcanti AB

Zampieri FG

Rosa RG

Abstract

<h4>Background</h4>Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.<h4>Methods</h4>We conducted a multicenter, randomized, open-label, three-group, controlled tri...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!